Molina Healthcare has delivered solid gains over the past year, yet its longer term share performance tells a more mixed story. That split track record puts fresh focus on a basic question for investors who follow the stock, whether the current price can be explained by the revenue the business brings in.
-
The share price has fallen 34.6% over the past 3 years, which puts pressure on the case that today's valuation is adequately supported by the company's sales base.
-
Recent updates on earnings, premium revenue and Medicaid margin trends suggest that future contract wins, pricing decisions and business exits can all influence how much value the market assigns to each dollar of Molina's revenue.
-
Your read on Molina Healthcare is one view; the desks covering it have another. See what analysts think Molina Healthcare's shares could be worth .
The stock's next move may depend on whether the current share price lines up with what Molina Healthcare's sales actually justify.
To cross check how Molina Healthcare's pricing stacks up against other potential ideas, a focused stock screen of 30 resilient stocks with low risk scores can be a useful next step in your research.
Is Molina Healthcare Still Cheap on Sales?
Molina Healthcare lends itself well to a P/S check because premium revenue is a core driver of how investors frame its value. Right now the stock trades on a P/S of about 0.3x, which is far below the broader healthcare industry average of roughly 1.4x and also below a peer group that averages about 1.9x. On this measure the market is paying a relatively low price for each dollar of Molina Healthcare's sales.
The fair multiple model, which blends factors like growth outlook, profitability, sector norms and risk profile, points to a higher P/S than the one the market currently assigns, so the shares screen as undervalued on this framework. Because management recently reaffirmed 2026 premium revenue guidance while also talking up future Medicaid rate resets and contract shifts, the current discount suggests investors are still cautious about how durable those cash flows and margins will be. Explore the numbers behind Molina Healthcare's P/S valuation .
The Molina Healthcare Narrative: What Would Justify Today's Price?
Narratives on Molina Healthcare pick up where the P/S puzzle leaves off and spell out which paths for growth, margins and earnings would need to play out for the stock to look meaningfully higher or lower than today's price, based on work shared on Simply Wall St's Community page. Rather than a single model output, each scenario lays out its own fair value assumptions so you can compare them with actual results as they come through.
The community is split between investors who see more upside in Molina Healthcare and others who think most of the story is already reflected in the price.
Bull case: 19% undervalued
"Embedded earnings that management estimates at $9 per share, compared with at least $5.25 of 2026 adjusted EPS guidance and at least $7.75 of estimated 2026 earnings power once Marketplace losses, MAPD drag and Florida CMS start up effects are stripped out, create room for Molina Healthcare to convert already committed contracts and margin actions into higher reported EPS..."
Discover why this Narrative puts Molina Healthcare at 19% undervalued .
Bear case: roughly fairly valued
"The current valuation implies the share price already reflects a fair outcome in which embedded earnings from Medicaid margin recovery, duals growth, and disciplined capital use are realised without major ACA or rate setting setbacks..."
Explore why this Narrative puts Molina Healthcare at roughly fairly valued .
One more angle on Molina Healthcare that could shift how you see the stock
There is one more checkpoint that can sharpen your view of Molina Healthcare, how professionals are mapping out the business a few years from now and how that compares with where the shares trade today. Explore where analysts expect Molina Healthcare to be in a few years .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include MOH .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
